Biotechnology giant CSL has reported net profit after tax for the six months ended December 31 of $1.9 billion, up 20 percent on the previous corresponding period. Underlying net profit was $2.02, set on revenue up 11 percent to $8.05 billion. CSL CEO and Managing Director Dr Paul McKenzie said: “Our strong first half result…
Biotechnology manufacturer CSL has failed to prove the efficacy of one of its most promising drugs under development – CSL112 (apolipoprotein A-I [human]). As recently as last year the Melbourne company was testing the drug in reducing the risk of follow on adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI) or…
Melbourne biotechnology giant CSL has hit back at doubters posting a massive rise in revenues for the year. The company, which has been questioned by analysts about its recent acquisition of the Vifor pharmaceutical business, reported revenues up 31 percent at constant currency value to $13.31 billion for FY23. Sales for CSL Vifor in the…
Australia’s largest manufacturer, biotechnology and vaccine producer CSL’s brand value has jumped more than 30 percent over the past year to make it the fastest growing brand in its industry, according to a new report from consultant Brand Finance. The report lists CSL’s brand value at US$1.3 billion, which is up 80 percent since 2020.…
Vaccine company CSL Seqirus has announced the ‘topping out’ of the construction of its biggest investment project, its new state-of-the-art manufacturing facility in Melbourne (pictured). The facility will use innovative technology to produce seasonal and pandemic cell-based influenza vaccines, CSL Seqirus’ vaccine adjuvant technology (MF59), the world’s only approved human vaccine for Q fever and…
A big jump in the volume of plasma produced by biotechnology giant CSL has created positive momentum for the Melbourne company as it continues its emergence from the global pandemic. The company reported a 36 percent increase in plasma collection in the first half – plasma collections sank during the pandemic as Covid restrictions affected…
Australia’s most valuable manufacturing company CSL has appointed Dr Paul McKenzie as its new CEO replacing Paul Perreault who has been in the role for 10 years. Perreault navigated the global vaccine and blood products company through the Covid pandemic, as well as further globalising the business. McKenzie previously served as CSL’s chief operating officer,…
Biotechnology and vaccine manufacturer CSL has licensed late stage self-amplifying mRNA vaccine platform technology from global vaccine developer Arcturus Therapeutics Holdings. Arcturus is developing next generation mRNA vaccines including a Covid-19 vaccine candidate that recently reported results from a major Phase 3 vaccine efficacy study. The vaccine candidate met its clinical goals in the study…
ASX-listed blood products and vaccine company CSL announced decarbonisation targets on Wednesday, with a goal of scope 1 and scope 2 emissions reduction of 40 per cent by 2030.
Analysis by Peter Roberts Australia’s largest and most successful manufacturer, global blood products and vaccine powerhouse CSL, is to raise billions from investors to execute a $17.2 billion all cash takeover of a complementary healthcare business, Swiss pharmaceutical manufacturer Vifor. The massive takeover expands CSL’s global footprint into complementary areas including haematology, thrombosis, cardiovascular and…
